Theanine
CAS 3081-61-6
Theanine (CAS 3081-61-6) is a Phase 3 pharmaceutical compound with 0 bioactivity targets and 147 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| THEANINE | 38022 | SU | MTHSPL |
| theanine | 38022 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Theanine used for in pharmaceutical contexts?
Theanine (CAS 3081-61-6) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Theanine?
Theanine has 147 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Abdominal pain, Acne cystic, Alopecia, Aphasia, Arthralgia. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Theanine also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Theanine with EU status "permitted".
What clinical phase is Theanine in?
Theanine is rendered with ChEMBL max phase 3.